Vaccine efficacy and effectiveness ကာကွယ်ဆေးထိရောက်မှု

ဆရာ ခင်ဗျ တခုလောက် မေးပါရစေ။ ကာကွယ်ဆေး ၉၅%၊ ၉၄.၅% ၅၀.၄% စသည် ဖြင့် ထိရောက် မူရှိတယ် ဆိုတာ ဘာလို နားလည် လို့ရမလဲ ခင်ဗျ။ ဥပမာ SINOVAC ဆိုရင် လူ ၁၀၀ ထိုးရင် ၅၀.၄ ယောက် ကရောဂါ ပိုးနဲ့ ထိတွေ့ တယ် ဒါပေမယ့် မကူးဘူး။ ၄၉.၆% က ကူးဆက် ခံရတယ်။ အဲလို ဆိုလို တာ လား ဆိုတာ လေး သိပါရစေ ခင်ဗျ။

Effectiveness ထိရောက်မှုဆိုတာ ကာကွယ်ဆေးတမျိုးကို ဆေးထိုးထားသူအုပ်စုနဲ့ ဆေးမထိုးသူအုပ်စု နှစ်ခုကို ယှဉ်ပြီး ကာလသတ်မှတ်ချက်အဆုံးမှာ ဘယ်လောက်အထိ ကာကွယ်မှုပေးသလဲကို ဆိုလိုတာဖြစ်တယ်။ ဘယ်ကာကွယ်ဆေးမှ ၁၀၀% တော့ မကာကွယ်နိုင်ပါ။

Duration of protection by vaccine
Disease  
Estimated duration of protection from vaccine after receipt of all recommended doses 1,2
Comments

Pertussis(whooping cough) 
4-6 years
Immunity from natural infection also wanes. Booster at age 11 years is offered

Diphtheria
Around 10 years
Boosters are recommended in adults at 45 & 65 years of age

Tetanus
96% protected 13-14 years, 72% >25 years
Boosters are recommended in adults at 45 & 65 years of age

Polio
>99% protected for at least 18 years
Boosters offered to those travelling to at risk countries

Haemophilus influenzae type B
>9 years to date
Excellent immunogenicity observed for this vaccine suggesting long-term protection

Hepatitis B
>20 years to date
Likely lifelong for those who have seroconverted but >20 years has been observed to date

Measles
Life-long in >96% vaccines
Community protection is important to stop transmission to those too young to be immunised, or those who cannot have the MMR vaccine

Mumps
 >10 years in 90%, waning slowly over time
 Duration of immunity varies in different populations. It is not as long-lived as measles or rubella

Rubella
Most vaccinees (>90%) protected >15-20 years
Community protection is important to stop transmission to those too young to be immunised, or those who cannot have the MMR vaccine

Pneumococcal
 >4-5 years so far for conjugate vaccines
To date antibody concentrations have remained high in vaccinees. Community protection means vaccinating children reduces the disease in all ages in the community

Human papillomavirus
>5-8 years to date
 Response following antigen challenge indicates immunity from vaccine likely to be very long term
Community immunity has been observed

Varicella
One dose - unknown
Two doses >14 years to date
Mild breakthrough disease can occur within 2 years when only one dose is given. Immunity is boosted when virus is still in circulation
Community immunity plays an important role is disease control

ဒေါက်တာတင့်ဆွေ

Comments

Popular posts from this blog

Hair Loss (1) ဆံပင်ကျွတ်ခြင်း (၁)

Omicron Positive အိုမီခရွန် ကူးစက်ခံရလျှင်

Ringworm ပွေး